Revolution Medicines' Daraxonrasib FDA Approval: A Game Changer for Biotech Investors
Revolution Medicines' FDA approval for daraxonrasib could signal significant gains for investors, with projected peak sales of $11.5 billion.
Protagonist Therapeutics Secures $275M Milestone with FDA Approval of MIMRYLO
Protagonist Therapeutics celebrates a pivotal $275M milestone as FDA approves MIMRYLO for polycythemia vera, signaling growth potential.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Moderna's Dual Catalysts: Bullish Sentiment Following Intismeran Success
Moderna's intismeran trial success and FDA approvals bolster bullish sentiment, signaling growth potential amidst stock …
Eli Lilly's Mounjaro FDA Approval: A Game Changer for Investors
Eli Lilly's Mounjaro receives FDA approval for cardiovascular risk reduction, signaling potential growth for investors.
Marvell Technology's Earnings Plunge: A Cautionary Tale for AI Investors
Marvell's stock dropped 8% post-earnings, highlighting the risks of high expectations in the tech sector.
Canada's GDP Growth Signals Economic Resilience Amid Inflation Concerns
Canada's Q2 GDP growth of 3.3% showcases resilience but raises inflation worries as traders eye the Bank of Canada's res…
Teva Pharmaceuticals Expands Neuroscience Portfolio with BXCL501 Acquisition Amid Growth Strategy
Teva Pharmaceuticals announces the proposed acquisition of BXCL501, enhancing its neuroscience pipeline under the 'Pivot…
Revolution Medicines Achieves FDA Approval for RASONQUE: A Game Changer or Pricing Overhang?
Revolution Medicines' RASONQUE received FDA approval, but high pricing and muted stock response raise concerns for inves…
Zymeworks (ZYME) Stock Soars After FDA Approval: Is It a Buy?
Zymeworks' stock takes flight post-FDA approval, suggesting a promising future in cancer treatment. Investors are intrig…
Merck (MRK) and Moderna (MRNA) Strike Gold in Melanoma Trial: What Investors Should Watch
Merck and Moderna's Phase 3 trial success could reshape cancer treatment and present new opportunities for investors.
Zymeworks' FDA Approval Sparks Analyst Optimism: What Investors Need to Know
Zymeworks' FDA approval for HER2+ cancer treatment has analysts bullish, raising the price target to $55 and indicating …